| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Adjusted EBITDA[1]of $14.4 Million, or $0.28 per Diluted Share |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 05 Oct 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market |
| 10 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
The architect of STAAR's global refractive transformation returns to lead STAAR's next commercial chapter as EVO ICL outpaces a declining laser refractive market |
| 18 Aug 2026 |
Form 4: Foust Warren, President and CEO
Received 10,997 shares by exercise or conversion · Gave up 5,595 shares to cover exercise price or tax ($146K) · Granted 22,493 Restricted Stock Units · 3 more |
| 18 Aug 2026 |
Form 4: Andrews Deborah J, Chief Financial Officer & EVP
Received 5,233 shares by exercise or conversion · Gave up 2,662 shares to cover exercise price or tax ($69.7K) · Granted 4,975 Restricted Stock Units · 3 more |
| 18 Aug 2026 |
Form 4: Michna Magda, Chief Development Officer
Received 6,599 shares by exercise or conversion · Gave up 3,356 shares to cover exercise price or tax ($87.9K) · Acquired 6,599 Performance Stock Units (Option Exercise/Conversion) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Adjusted EBITDA1 of $20.0 million, or $0.39 per diluted share |
| 06 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
STAAR Surgical Company, a Delaware corporation, (the “Company”), pursuant to its Amended and Restated Omnibus Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the individual listed below (“Partici... |
| 04 Aug 2026 |
Form 4: Foust Warren, President and CEO
Received 20,787 shares by exercise or conversion · Gave up 10,576 shares to cover exercise price or tax ($258K) |
| 04 Aug 2026 |
Form 4: Andrews Deborah J, Chief Financial Officer & EVP
Received 13,955 shares by exercise or conversion · Gave up 6,480 shares to cover exercise price or tax ($202K) · Received 20,787 shares by exercise or conversion · 1 more |
| 24 Jun 2026 | S-8 |
| 23 Jun 2026 |
Form 4: Wang Christopher Min Fang, Director
Granted 11,145 Common Stock Option |
| 22 Jun 2026 |
Form 4: LeBuhn Richard T., Director
Granted 11,145 OPTION TO PURCHASE COMMON STOCK |
| 22 Jun 2026 |
Form 4: Bradsher Neal C, Director
Granted 11,145 OPTION TO PURCHASE COMMON STOCK |
| 22 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
This Amendment No. 2 (the “Amendment No. 2”) to the STAAR Surgical Company Amended and Restated Omnibus Equity Incentive Plan (the “Plan”) is adopted by the Board of Directors (“Board”) of STAAR Surgical Company, a Delaware corporation (... |
Loading...